Send to

Choose Destination
Front Oncol. 2014 Sep 11;4:224. doi: 10.3389/fonc.2014.00224. eCollection 2014.

Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.

Author information

Immunologisches Onkologisches Zentrum Köln , Cologne , Germany.
German Cancer Research Institute , Heidelberg , Germany.


This paper focuses on oncolytic Newcastle disease virus (NDV). This paper summarizes (i) the peculiarities of this virus as an anti-cancer and immune stimulatory agent and (ii) the approaches to further harness this virus as a vector to combat cancer. Special emphasis is given on combining virus therapy with cell therapy and on improving tumor targeting. The review will include some of the authors work on NDV, bi-specific antibodies, and cell therapy as building blocks for a new perspective of multimodal cancer therapy. The broad anti-tumor immune reactivation includes innate and adaptive, tumor antigen (TA) specific and TA independent activities.


Newcastle disease virus; T-cells; bi-specific antibodies; cellular therapy; dendritic cells; hyperthermia; tumor targeting

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center